1[1]Albrigt F， Rifenstem C. The parathyroid glands and metabolic bone disease. Baltimone: William and Wilkins Company, 1948.78.
2[2]Herschberger LG, et al. Myotrophic activity of 19 nortestosterone and other steroids determined by the modified levator muscle method. Proc Soc Exp Biol Med,1953,83:175-180.
3[3]Markiewisz L, Gurpide E. In vitro evaluation of estrogenic,estrogenic antagonistic effects of a steroidal drug (Org OD14)and its metabolites on human endometrium. J Steroid Biochem,1990,35:535-541.
4[4]Rymer J, et al. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int,1994,4:314-317.
5[5]Gompel A, et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol,1997,11(Suppl1):77-79.
6[6]Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet, 1997,350:1047-1059.
7[7]Bjamason NH, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab,1997,82:1752-1756.
8[8]Haenggi W, et al. Long-term influence of different postmenopausal hormone replacemnt regimes on serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol,1997,104:708-717.
9[9]DeAloysic D, et al. Use of Org OD14 for the treatment of climacteric complaints. Maturitas,1987,(Supp 1):49-65.
